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ABO BLOOD GROUP ANTIBODIES AFTER ALLOGENEIC HEMATOPOI-
ETIC STEM CELL TRANSPLANTATION
Stussi, G.1, Huggel, K.1, Schanz, U.1, Halter, J.1, Passweg, J.R.2,
Gratwohl, A.2, Seebach, J.D.1 1. University Hospital, Zuerich, Swit-
zerland; 2. University Hospital, Basel, Switzerland.
Aside from causing hemolytic reactions the ABO blood group
system does not have a major impact on the outcome after alloge-
neic hematopoietic stem cell transplantation (HSCT). However,
only limited studies have analyzed the importance of anti-A/B
antibodies after HSCT. In particular, after minor and bidirectional
ABO-incompatible HSCT, donor B lymphocytes may produce
anti-recipient ABO antibodies. We developed a new method using
ﬂow cytometry (FACS) to quantify anti-A/B antibodies after
HSCT. Repetitive serum samples of 16 patients (ABO-identical 5,
major 4, minor 4, bidirectional 3) receiving allogeneic HSCT were
analyzed by FACS and agglutination assay with a mean follow-up
time of 486 days (range: 22-810 days). Most patients received
HSCT for acute or chronic leukemia (AML 43%, CML 31%) and
in 50% of the cases peripheral blood was used as stem cell source.
In a preliminary analysis, we did not ﬁnd an elevation of anti-
recipient ABO-antibodies after minor or bidirectional ABO-in-
compatible HSCT. None of these patients had clinical signs of
hemolysis or bilirubin elevations. In general, anti-A/B IgM and
IgG gradually decreased after transplantation. However, in some
cases, posttransplant anti-A/B antibody levels approached donor
antibody levels, and in 2 additional patients, elevation of recipient
anti-A/B antibodies correlated with the incidence of relapse. All
data obtained by FACS analysis correlated well with the results
obtained by agglutination assays. In conclusion, no transient ele-
vation of anti-recipient ABO antibodies after minor ABO-incom-
patible HSCT was observed in 7 patients receiving minor or
bidirectional ABO-incompatible HSCT. The general reduction of
ABO antibody levels after HSCT might be a consequence of the
immunosuppressive regimen. In some cases, however, the reap-
pearance of recipient ABO antibodies seems to correlate with the
relapse of leukemic disease.
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TEMPORALLY DISCORDANT GRAFT VERSUS LEUKEMIA (GVL) AND
GRAFT VERSUS HOST (GVH) RESPONSES AFTER DONOR LYMPHOCYTE
INFUSION THERAPY FOR RELAPSED CHRONIC MYELOGENOUS LEUKE-
MIA
Hari, P.N., Drobyski, W.R. Medical College of Wisconsin, Milwaukee,
WI.
Separation of GVL and GVH reactivity after allogeneic hema-
topoietic stem cell transplantation remains an elusive clinical goal.
We have previously observed in murine models that GVL and
GVH reactivity can be dissociated based on temporal kinetics
whereby the GVL effect antedates GVHD allowing mice mice to
eliminate leukemia before they develop lethal GVHD (J Immunol
170:2003). To determine if this observation was relevant to man,
we examined the tempo of GVL and GVH reactivity in a cohort of
patients receiving DLI for relapsed CML where the kinetics of
these responses could be examined in the absence of the confound-
ing effects of the conditioning regimen and immunosuppressive
therapy. Between 1992-2002, 38 patients with relapsed CML after
allogeneic BMT from either HLA-identical sibling or unrelated
donors were treated with DLI. Patients were excluded if they did
not have both an antileukemic response and GVHD after DLI
(n  16) or were administered prolonged (2 weeks) IFN therapy
after DLI to control blood counts (n  4). The remaining 18
patients were in either accelerated phase 4/18 (22%), chronic phase
9/18 (50%), cytogenetic relapse 4/18 (22%), or molecular relapse
1/18 (5%) at time of DLI. All had sustained cytogenetic (CGR)
and/or molecular responses (MR)(Houston criteria) attributable to
DLI along with documented clinical GVHD. The median time to
earliest cytogenetic or molecular response was 53 days (20 -97)
while time to complete cytogenetic or molecular remission was 82
days (32 -230). The inital onset of GVHD occurred at a median of
59 days (32 -157) in the entire patient cohort. Eleven of 18 patients
had evidence of a CGR or MR that occurred a median of 22 days
(range 5-121)before onset of GVHD. In 4 patients a CGR or MR
was documented concurrently with GVHD, indicating that a GVL
response had already occurred before GVHD became clinically
evident, while in 3 patients GVHD developed before an antileu-
kemic response was observed. In 7 patients, the CGR or MR was
already complete before GVHD began and antedated the onset of
GVHD by a median of 14 days (range 0-84). These data indicate
that GVH and GVL responses are not synchronous events but can
occur with temporally discordant kinetics. These data also provide
rationale for therapeutic strategies designed to dissociate these two
events after allogeneic SCT by the targeted elimination of allo-
reactive donor T cells after the GVL effect has occurred but before
clinical GVHD has developed.
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CROSS-PROTECTIVE T CELL RESPONSES TO MURINE MYELOID LEU-
KEMIAS ARE REVEALED BY CHARACTERIZATION OF THE CD8 T CELL
REPERTOIRE
Lewandowski, A.M., Friedman, T.M., Castor, D., Korngold, R. Jeffer-
son Medical College, Kimmel Cancer Center, Philadelphia, PA.
Three heterologous c-myc retrovirus-transformed myeloid leu-
kemia lines (MMB 1.10, MMB2.18, and MMB3.19) of C57BL/6
(B6; H2b) origin were used to investigate graft-versus-leukemia
(GVL) activity in murine bone marrow transplantation models.
The transfer of B6 CD8 T cells, from mice appropriately pre-
sensitized to each individual myeloid leukemia, to bone marrow
reconstituted syngeneic recipients could mediate effective GVL
protection against the speciﬁc leukemic challenge. In addition,
MMB3.19-primed B6 CD8 T cells provided a cross-protective
GVL effect against challenge with the MMB1.10 and MMB2.18
cells. In order to better characterize the B6 CD8 T cell anti-
leukemia responses, T cell receptor V CDR3-size spectratype
analysis was performed after in vivo stimulation with each individ-
ual leukemia line. The spectratype results indicated both unique
and overlapping skewing patterns between the leukemia-reactive
populations, suggesting the recognition of both shared and distinct
tumor antigens. V 2, 11, and 12 families were uniquely involved
in the anti-MMB2.18 response, whereas involvement of the V 7
family was unique to the anti-MMB3.19 and MMB1.10 responses.
On the other hand, V 3 and 6 families were similarly skewed in
response to all three leukemia lines. These ﬁndings were translated
back to the in vivo model, whereby infusion of uniquely reactive
V subpopulations of presensitized B6 CD8 T cells caused sig-
niﬁcant GVL activity against challenge with the corresponding
leukemia line, after syngeneic bone marrow transplantation. How-
ever, signiﬁcant GVL protection was not observed in groups chal-
lenged with the non-overlapping leukemia lines. Conversely, infu-
sion of the shared reactive V3 and 6 subpopulations protected B6
recipients from challenge with all three MMB cell lines. These
results demonstrated that syngeneic CD8 T cell responses can be
generated that are targeted at either unique or shared myeloid
leukemia antigens. A better understanding of the precise nature of
these anti-leukemia responses and identiﬁcation of their corre-
sponding leukemia tumor antigens may provide insight into the use
of ex vivo stimulated autologous T cells for treatment of acute
(AML) and chronic (CML) myelogenous leukemia.
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DISTINCT DIFFERENCES IN GVHD EFFECTOR ACTIVITY AMONG DONOR
CD8 POPULATIONS: ENGRAFTMENT WITHOUT GVHD USING THE
FACILITATING CELL
Kazerounian, S., Glickman, J.N., Wright, R.D., Napoli, R., Colson,
Y.L. Brigham and Women’s Hospital/Harvard Medical School, Boston,
MA.
INTRODUCTION: Bone marrow transplantation (BMT) is the
current treatment of choice for a variety of hematologic disorders,
and solid tumors. However, graft-versus-host disease (GVHD) and
failure of engraftment have limited this treatment option to the
30% of patients with a closely matched donor. Removal of T cells,
and cells which express markers shared by T cells decreases the
severity of GVHD but increases the incidence of graft failure.
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Recent evidence has suggested that allogeneic engraftment failure
of puriﬁed hematopoietic stem cells (HSC) can be decreased by
including a BM-derived CD8/TCR- facilitating cell (FC) or
CD8

/TCR T cell populations. Therefore, the present study
investigated the clinically important question of GVHD effector
activity of these donor CD8 populations in the setting of HSC
transplantation. METHODS: A puriﬁed cell component-based
model of lethal GVHD was established using a P3 F1
(B63 B6D2F1) murine model. All recipients were lethally irradi-
ated and reconstituted with as few as 2000 puriﬁed HSC (Sca
ckit Lin-) of donor alone or together with one of the following
lymphoid subsets: 1) TCR splenic T cells; 2) CD8/TCR
BM-derived T cells (TBM) and 3) the CD8/TCR- FC popu-
lation. RESULTS: As expected, all recipients of puriﬁed HSC
exhibited little evidence of GVHD with clinical scores of 1.60.3,
on a ﬁve parameter clinical scale ranging from 0 to 10. Addition of
puriﬁed TCR splenocytes in the donor inoculum, as a positive
effector control, resulted in lethal GVHD with a 50% mortality
and a clinical score of 4.30.9. Similarly, recipients of HSC plus
BM-derived CD8 T cells rapidly exhibited lethal GVHD with
decreased survival and signiﬁcant morbidity (4.30.7). In marked
contrast, no clinical evidence of GVHD was present in recipients
of HSCFC (1.550.1). Histological analysis of the gut demon-
strated minimal to no evidence of GVHD in 85% of these recip-
ients whereas 57% of HSCTBM demonstrated moderate to se-
vere GVHD. CONCLUSION: These ﬁndings suggest that in
contrast to CD8 TBM, the FC, which expresses a unique FCp33-
TCR heterodimer in place of TCR, does not result in signif-
icant GVHD even in an aggressive P3 F1 model. Therefore,
supplementation of the donor inoculum with the FC has the
potential to offer a safer, more efﬁcient approach to enhance
alloengraftment in the absence of GVHD.
HISTOCOMPATIBILITY/ALTERNATIVE STEM
CELL SOURCES
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RAPID CONVERSION TO FULL CHIMERISM AFTER REDUCED INTENSITY
CONDITIONING (RIC) AND TRANSPLANTATION OF T-CELL DEPLETED
LARGE NUMBERS OF CD34 STEM AND CD56 NATURAL KILLER
(NK) CELLS OBTAINED FROM MOBILIZED HAPLOIDENTICAL DONORS
Benaim, E., Hale, G., Horwitz, E., Leung, W., Woodard, P., Yusuf, U.,
Handgretinger, R. St Jude Children’s Research Hospital, Memphis, TN.
Since alloreactive NK cells have recently been described to exert
an anti-leukemic effect, to reduce GvHD and to facilitate engraft-
ment across HLA-barriers, we have designed a protocol to pro-
mote rapid engraftment of haploidentical stem cells after Reduced
Intensity Conditioning (RIC) in patients with refractory hemato-
logical malignancies. Haploidentical donors (if available, NK-allo-
reactive donors were preferentially chosen and 5 out of 8 donors
had a constellation of NK-alloreactivity) were mobilized using
G-CSF and/or GGM-CSF. In order to cotransplant large num-
bers of CD56 NK cells together with stem cells, PBSCs were
negatively depleted of T-lymphocytes using an anti-CD3 mono-
clonal antibody conjugated to magnetic microbeads and high gra-
dient magnetic cell sorting utilizing the automated CliniMACS
device (Miltenyi Biotec).The RIC regimen included Fludarabine
(200 mg/m2), Thiotepa (10 mg/m2) and Melphalan (60 to 140
mg/m2). Rituximab (375 mg/m2) was given prior to the stem cell
infusion. Immunosuppressive regimen included Muromonab-CD3
(OKT3) and Cyclosporine or Mycophenolate mofetil. We trans-
planted 8 patients (5 AML-relapse, 1 therapy-related secondary
MDS, 1 Biphenotypic leukemia-CR2, 1 CML-blastic crisis). 5
patients have received a previous allogeneic HSCT. The mean
total MNC, CD34 and CD3 cell counts per kg infused were
8.16 x 108 (2.6 -15 x 108), 15.13 x106 (2.14-37.54 x 106) and 0.243
x 106 (0.01-0.476 x 106) respectively. The number of infused
CD56 NK cells ranged from 44 to 200 x 106/kg. All patients
achieve early 100% peripheral blood donor chimerisms with a
median of 14.5 (8-20) days. 7 patients achieve primary engraftment
(ANC  500) at a mean of 11.14 (7-14) days. One patient had only
early lymphoid engraftment. He was successfully engrafted by day
45 after repeated plasmapheresis and a stem cell boost. No early
transplant-related mortality was seen. 3 patients had transient
grade 1-2 skin GVHD that was controlled with immunosuppres-
sion and 1 patient developed liver GvHD. 5 of the 8 patients are
alive with short follow-up. Overall, patients tolerated the RIC well
and achieved very rapid chimeric engraftment. Haploidentical
transplantation of T-cell depleted PBSC after RIC might be a
therapeutic option for patients with advanced malignant diseases
and a platform for further exploiting the role of alloreactive NK
cells in the reduction of GvHD and the facilitation of engraftment
in patients with nonmalignant diseases.
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ALLOGENEIC STEM-CELL TRANSPLANTATION WITH MATCHED UNRE-
LATED DONORS IN ELDERLY PATIENTS (55-67 YEARS); AGE BY ITSELF
IS NO LONGER A CONTRAINDICATION
Shimoni, A.1, Kroger, N.2, Zander, A.R.2, Yeshurun, M.1, Hardan, I.1,
Nagler, A.1 1. Chaim Sheba Medical Center, Tel-Hashomer, Israel; 2.
University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Allogeneic stem-cell transplantation (SCT) is a potentially cura-
tive approach for patients (pts) with hematologic malignancies.
The introduction of low-intensity conditioning (LIC) regimens
reduced SCT-related toxicity and allowed treatment of elderly pts.
However, there is only limited data on the feasibility of this
approach in SCT using unrelated donors, in elderly pts over age 55
years. Thirty-ﬁve pts were included in this study. The median age
was 58 years (range, 55-67). Eleven pts were age 60 and above at
the time of SCT. Diagnoses included myeloid malignancies (n 
22); AML (n  13, 8 secondary), MDS (n  4), CML (n  3),
myeloﬁbrosis (n  2), and lymphoid malignancies (n  13); mul-
tiple myeloma (n  9) and non-Hodgkin’s lymphoma (n  4).
Conditioning regimens included ﬂudarabine (F) and busulfan (FB,
n 16), F and melphalan (FM, n 12), F and treosulfan (FT, n
5), and F and low-dose TBI (n  2). All pts were also given ATG
during conditioning. With a median follow-up of one year, 18 pts
are alive and 16 are disease-free. The 1-year OS and DFS are 46
10%, and 3311%, respectively. Five pts died of disease progres-
sion, and 12 of treatment-related causes (TRM), including acute
GVHD (n 2), infection (n 2), liver toxicity (n 3), pulmonary
toxicity (n  2), TTP (n  2), and heart failure (n  1). The
estimated risk for TRM was 379%. A limited multivariant anal-
ysis identiﬁed conditioning with FM (rather than FB or FT), and
diagnosis of lymphoid malignancy as risk factors for TRM with
hazard ratios of 21.6 (p  0.02) and 11.2 (p  0.05), respectively.
Age category was not predictive of TRM; only 2 of the 11 pts over
age 60 had TRM. Pt or donor gender and disease status at SCT
were also not signiﬁcant risk factors. Pt number and follow-up
duration are too small to assess risk factors for OS and DFS. When
only the 20 pts with myeloid malignancies conditioned with FB or
FT were analyzed, the estimated TRM, OS and DFS rates were
2811%, 6012% and 6012%, respectively. In conclusion,
SCT from unrelated donors is feasible in selected groups of elderly
patients when using LIC regimens. Toxicity is acceptable and not
signiﬁcantly different from that observed in younger patients. Fa-
vorable outcome was observed in myeloid malignancies. Age by
itself should not rule out SCT from unrelated donors.
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A COMBINATIONAL METHOD TO IDENTIFY HLA-DRB1*0401 INDIVID-
UALS FOR IMMUNOTHERAPEUTIC STUDIES
Huang, X.1, Gebe, J.A.2, Blazar, B.1, Zhou, X.1 1. University of
Minnesota Cancer Center, Department of Pediatrics, Division of Blood
and Marrow Transplantation, Minneapolis, MN; 2. Benaroya Research
Institute at Virginia Mason, Seattle, WA.
HLA-DR4 is present at high frequencies in many populations and
presents many well-characterized peptide antigens to T cells in dis-
eases including infection, autoimmune disorders, transplant rejection
and cancer. We have established a combinational, simple and eco-
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